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Granulocyte-Colony–Stimulating Factor Mobilizes Bone
Marrow Stem Cells in Patients With Subacute
Ischemic Stroke
The Stem Cell Trial of Recovery EnhanceMent After Stroke (STEMS)
Pilot Randomized, Controlled Trial (ISRCTN 16784092)
Nikola Sprigg, MRCP; Philip M. Bath, MD; Lian Zhao, PhD; Mark R. Willmot, MRCP;
Laura J. Gray, MSc; Marion F. Walker, PhD; Martin S. Dennis, MD; Nigel Russell, MD
Background and Purpose—Loss of motor function is common after stroke and leads to significant chronic disability. Stem
cells are capable of self-renewal and of differentiating into multiple cell types, including neurones, glia, and vascular
cells. We assessed the safety of granulocyte-colony–stimulating factor (G-CSF) after stroke and its effect on circulating
CD34 stem cells.
Methods—We performed a 2-center, dose-escalation, double-blind, randomized, placebo-controlled pilot trial (ISRCTN
16784092) of G-CSF (6 blocks of 1 to 10 g/kg SC, 1 or 5 daily doses) in 36 patients with recent ischemic stroke.
Circulating CD34 stem cells were measured by flow cytometry; blood counts and measures of safety and functional
outcome were also monitored. All measures were made blinded to treatment.
Results—Thirty-six patients, whose meanSD age was 768 years and of whom 50% were male, were recruited. G-CSF
(5 days of 10 g/kg) increased CD34 count in a dose-dependent manner, from 2.5 to 37.7 at day 5 (area under curve,
P0.005). A dose-dependent rise in white cell count (P0.001) was also seen. There was no difference between
treatment groups in the number of patients with serious adverse events: G-CSF, 7/24 (29%) versus placebo 3/12 (25%),
or in their dependence (modified Rankin Scale, median 4, interquartile range, 3 to 5) at 90 days.
Conclusions—G-CSF is effective at mobilizing bone marrow CD34 stem cells in patients with recent ischemic stroke.
Administration is feasible and appears to be safe and well tolerated. The fate of mobilized cells and their effect on
functional outcome remain to be determined. (Stroke. 2006;37:2979-2983.)
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Recovery after stroke is improved with thrombolysis oraspirin use and management in a stroke unit. The brain’s
capacity to undergo dynamic and plastic change means that it
may be possible to enhance recovery by pharmacological
means (pharmacological rehabilitation, eg, with amphet-
amine) or the use of stem cells (neuroreparative therapy).1
Stem cells have the capacity to self-renew and differentiate
into different cell types, including neurons, astrocytes, and
endothelial cells. Stem and progenitor cells are present in
fetal cells, immortalized cell lines, umbilical cord blood, bone
marrow, and specific organs, including the brain. Animal
studies suggest that stem cells (including those from bone
marrow) can survive, integrate, and function as neurons in
experimental models of stroke.2–4 Nevertheless, between- and
within-species transplantation of cells is fraught with prob-
lems (including infection, rejection, risk of malignancy, and
ethical considerations),5 and stimulation of endogenous stem
cell pools might be preferable.6
Granulocyte-colony–stimulating factor (G-CSF) is a
growth factor that acts on hematopoietic stem (CD34) cells
to regulate neutrophil progenitor proliferation and differenti-
ation. G-CSF is routinely used to mobilize stem cells for
transplantation in patients with hematological malignancy.
Data support its use in healthy donors and older people with
hematological malignancy, whereas experimentally, G-CSF
has been assessed in patients with multiple sclerosis.7–9
G-CSF does not appear to induce platelet aggregation or
microembolism.10,11 In experimental models of stroke (in
mice and rats), G-CSF exhibited neuroprotective and regen-
erative activity, including recruiting neural progenitor cells,
reducing cerebral edema, improving survival, and enhancing
sensorimotor and functional recovery.12–18 This multimodal
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behavior of G-CSF means that it is a candidate treatment for
enhancing recovery after stroke, although no clinical studies




We performed a prospective, 2-center, double-blind, dose-escalation,
randomized, placebo-controlled, Phase IIa trial of G-CSF in patients
with subacute ischemic stroke. A dose-escalation design was used,
because the effects of G-CSF on stem cell mobilization are poorly
documented in elderly patients with significant comorbid disease,
and it was conceivable that the marrow would be either under- or
supersensitive to therapy. Such designs are frequent in stroke.19
The study was approved by the Nottingham Local Research
Committee (June 5, 2003), had a Medicines and Healthcare Products
Regulatory Agency Clinical Trial Authorization (March 10, 2003),
was registered for a trial number (ISRCTN 16784092), and was
performed according to the Declaration of Helsinki and the Interna-
tional Conference on Harmonization of Good Clinical Practice.
Subjects
Adult patients with recent (7 to 30 days postictus) ischemic stroke
and motor weakness (arm and/or leg, MRC grade 5/5) were
identified and enrolled from Nottingham City Hospital (NCH) and
Queen’s Medical Centre (QMC) by M.R.W. and N.S. Treatment was
not given during the first 7 days after ictus because we did not wish
to exacerbate the normal leukocytosis seen during acute stroke with
G-CSF, which also increases leukocyte count. The principal exclu-
sion criteria included premorbid dependency (modified Rankin scale
[mRS] 3), primary intracerebral hemorrhage, dementia, coma,
malignancy, sickle cell disease, and pregnancy. Full written, in-
formed consent was obtained from patients before randomization, or
assent was received from a relative/caregiver if the patient was
incompetent owing to being obtunded, confused, or dysphasic.
Intervention
Patients were randomized to receive either subcutaneous human
recombinant G-CSF (filgastrim, Amgen; purchased from the hospi-
tals’ pharmacies) or placebo (saline) in a dose-escalation design.
Dose blocks comprised 6 patients (4 active and 2 placebo in random
order) and ranged from 1 dose of 1 g/kg (105 U/kg) to 5 daily doses
of 10 g/kg (106 U/kg; Figure 1); the latter dose is standard after
bone marrow transplantation. When designing the protocol, we had
allowed higher doses (30 g/kg given either once or daily for 5 days)
to be given, depending on the achieved CD34 count; review by the
Data Monitoring Committee advised that testing of these doses
would be unnecessary. Computerized randomization was performed
with minimization on age, sex, baseline severity (Scandinavian
Neurological Stroke Scale [SNSS]), and baseline CD34 and
leukocyte counts.
Outcomes
The primary outcome was peak circulating blood CD34 count,
with the aim of achieving a CD34 count of 10 cells/L;
measurements were made on days 1, 3, 5, 7, and 10. Full blood
counts and assessment of tolerability were performed in parallel with
CD34 counts. Safety was assessed as mortality, impairment
(SNSS), disability (Barthel Index [BI]), dependence (mRS), and
serious adverse events at days 10 and 90. Specific clinical informa-
tion on musculoskeletal pain, splenomegaly, thrombocytopenia,
proteinuria, infection, and venous thromboembolism was also rec-
orded. Laboratory and clinical measurements were performed
blinded to each other and to treatment assignment.
Laboratory Measures
CD34 count was performed by flow cytometry (FACScalibur,
Becton Dickinson, Oxford, UK). Blood cells were labeled with
fluorescein isothiocyanate- and phycoerythrin-tagged antibodies
against CD34 and added to tubes containing latex beads (Tru-
Count, Becton Dickinson).20 Full blood counts were analyzed by the
NCH and QMC Hematology Department staff using standard hema-
tology analysers. C-reactive protein (CRP) was measured with a
commercial high-sensitivity, wide-range ELISA kit (Kalon Biolog-
ical Ltd, Aldershot, UK).
Statistical Methods
Data on CD34, full blood count, and safety (serious adverse
events, death, impairment) were assessed after each dosing block of
6 patients by the Data Monitoring Committee (comprising M.S.D.,
N.R., and P.M.B.). A decision was then made on whether to proceed
to the next dosing block. Data on other measures were pooled by
treatment group. The primary analysis was peak CD34; peak blood
count parameters and comparison of areas under the curve (AUCs)
across 10 days were also performed for CD34, blood counts, and
temperature. Data are presented as mean (with SD), median (with
interquartile range [IQR]), or number (and percentage) and were
analyzed with Fisher’s exact test, Mann-Whitney U test, ANCOVA,
Kruskal-Wallis test, or ordinal logistic regression, as appropriate. All
analyses were performed with SPSS (Apple Mac, version 11; SPSS




Thirty-six patients were enrolled between August 2003 and
November 2005 (Figure 1). The baseline characteristics were
matched for age, sex (Table 1), and baseline CD34 (Table
2). Patients randomized to G-CSF had a trend to milder stroke
(SNSS) and were more likely to have a history of diabetes
(P0.07). Patients were enrolled between 7 and 28 days after
stroke, G-CSF median of 14 days (IQR, 10–18), and control
median of 12 days (IQR, 10 to 17). No patients were lost to
Figure 1. Trial design.
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follow-up, and all patients received all prescribed G-CSF or
placebo injections.
CD34, Blood Counts, and CRP
G-CSF increased CD34 in a dose-dependent manner, with
the peak level occurring at day 5; the highest dose of G-CSF
(5 days of 10 g/kg) achieved a 15-fold increase in CD34
compared with placebo (AUC, P0.005; Table 2 and Figure
2). The total leukocyte count also increased in a dose-
dependent manner (P0.001); most of this response was
driven by increases in neutrophil count (data not shown).
There was no significant relation with platelet count, although
laboratory thrombocytopenia (platelet count 150 without
clinical features) was noted in 2 (8%) G-CSF patients versus
0 in the control group; no cases of clinical thrombocytopenia
or hemorrhage were observed. Erythrocyte counts did not
change with G-CSF. Additionally, G-CSF did not alter CRP
levels at 5 days (with adjustment for levels at baseline):
G-CSF mean 42.9 g/L (SD, 25.1) versus placebo 41.9 g/L
(SD, 30.1) (ANCOVA, P0.747).
Safety
Five patients (3 G-CSF and 2 placebo) died during the course
of the study (Table 3). One patient died on day 10, and the
remaining 4 died after completion of the treatment phase
(Table 4). During the study, 1 recurrent stroke occurred (1
G-CSF 1) after completion of the treatment phase. Rates of
infection and venous thromboembolism did not differ be-
tween patients randomized to G-CSF and placebo (Table 3).
Adverse events were not related to dose (Table 3). Temper-
ature did not differ between the treatment groups. Spleno-
megaly was not detected in any patient.
Impairment (SNSS), disability (BI), and dependence (mRS)
were also assessed as measures of safety and did not differ
between the treatment groups at either day 10 or day 90 (Table
4). There was no difference in functional outcome with different
doses of G-CSF (Kruskal-Wallis P0.837; data not shown).
The apparent difference in median BI score at day 90 (G-CSF 43
versus control 63) was nonsignificant in both univariate (Table
4) and baseline covariate-adjusted (age and SNSS; ordinal
logistic regression, P0.18; data not shown) analyses.
Discussion
This is the first Phase IIa dose-escalation clinical trial to
assess G-CSF in patients with stroke. We found that G-CSF
was effective in mobilizing CD34 stem cells into the
peripheral bloodstream in subacute ischemic stroke. In par-
ticular, 5 daily doses of 10 g/kg G-CSF, as is used in
hematological malignancies, increased CD34 counts by
15-fold and achieved a mean peak of 37.7 cells/L. Preclin-
ical data suggest that G-CSF has both neuroprotective and
neuroreparative properties.12–18,21 Mobilized bone marrow
stem cells could home into the damaged brain after stroke and
promote cytogenesis, either by direct clonal expansion and
transdifferentiation into neurones, glia, and vascular cells or
through stimulation of local brain progenitor cells and enrich-
ment of the local milieu.17 Our experimental protocol was
solely based around a neuroreparative paradigm, and we did
TABLE 2. Peripheral Blood CD34 Count (cells/l) by Treatment Dose and No. of Treatments
Dose Doses Day 0* Day 1 Day 3 Day 5 Day 7 Day 10
0 1 or 5 3.0 (1.2) 3.9 (1.2) 3.6 (1.1) 3.3 (1.0) 3.8 (2.3) 3.5 (1.2)
1 g/kg 1 3.4 (2.4) 6.1 (8.4) 5.5 (4.1) 3.6 (1.3) 1.8 (0.8) 2.2 (1.1)
3 g/kg 1 3.1 (0.8) 4.0 (0.8) 6.3 (2.5) 6.1 (2.5) 4.3 (1.8) 3.0 (1.7)
10 g/kg 1 2.8 (1.7) 3.0 (1.5) 5.0 (2.5) 3.7 (2.1) 3.0 (1.7) 4.3 (2.7)
1 g/kg 5 3.9 (1.1) 3.4 (0.7) 4.1 (1.9) 6.3 (0.5) 8.2 (2.1) 4.8 (1.4)
3 g/kg 5 2.2 (1.1) 3.1 (1.1) 11.2 (1.5) 19.1 (7.9) 20.0 (6.0) 8.7 (9.3)
10 g/kg 5 2.5 (1.3) 10.1 (7.3) 22.4 (17.2) 37.7 (36.7) 19.8 (11.1) 6.5 (1.4)
All – 3.0 (1.4) 4.6 (4.0) 7.0 (8.1) 9.8 (15.9) 7.4 (7.8) 4.3 (3.2)
The dose and No. of treatments reflect the order used in the trial. Mean (SD).
Day 0 is baseline. *Minimization variable.
TABLE 1. Baseline Characteristics of Patients.
Characteristic Placebo (n12) G-CSF (n24)
Age (years)†* 74 (8) 76 (9)
Male* 6 (50) 12 (50)
SNSS* 21 14–33 26 21–41
Time to treatment (days)† 13 (4) 14 (5)
Clinical stroke syndrome29
Lacunar 4 (33) 5 (21)
Partial anterior circulation 3 (25) 11 (46)
Total anterior circulation 5 (42) 8 (33)
TOAST aetiological group30
Small vessel disease 5 (42) 7 (29)
Large artery disease 1 (8) 2 (8)
Cardio-embolic stroke 2 (17) 11 (46)
Previous hypertension 6 (50) 18 (75)
Hyperlipidaemia 2 (17) 8 (33)
History of diabetes 0 (0) 7 (29)
Atrial fibrillation 2 (17) 10 (42)
Previous stroke 3 (25) 6 (25)
Previous ischaemic heart disease 2 (17) 8 (33)
Peripheral arterial disease 1 (8) 1 (4)
Anti-platelet treatment‡ 9 (75) 18 (75)
Statin treatment‡ 11 (92) 15 (63)
No. (%), mean† (SD) or median IQR.
SNSS (low numbers signify severe stroke); *Minimization variables; ‡con-
current treatment at time of randomization.
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not test the neuroprotective hypothesis, because we deliber-
ately started treatment 7 or more days after ictus to avoid
exacerbating the normal leukocytosis seen after ischemic
stroke.
Treatment with G-CSF was associated with a dose-dependent
increase in the mean leukocyte count from 8.5 to 36.4 at the
highest dose (P0.001). Moderate laboratory thrombocytope-
nia, another recognized effect of G-CSF, occurred in 2 patients
but did not lead to any clinical sequale. No difference in serious
adverse events was seen between the treatment groups, and
G-CSF treatment was not associated with infection or thrombo-
embolic events. Other recognized adverse effects of G-CSF,
such as musculoskeletal pain and splenomegaly, were not seen.
Overall, the drug was well tolerated. All doses of treatment were
administered, supporting the tolerability and feasibility of the
treatment. No differences in functional outcome were noted
between treatment groups or G-CSF dose, although the trial had
minimal power to detect these.
A very small, nonplacebo-controlled, randomized trial involv-
ing just 10 patients (7 G-CSF and 3 control) with acute stroke
has been published recently.22 The investigators found that
G-CSF treatment was well tolerated, was not associated with
serious adverse events, and might improve neurological func-
tion. G-CSF has also been administered to patients with other
vascular disease. The results of the 4 published randomized trials
in patients with acute myocardial infarction vary, in part because
of their small size and different dosing regimes.23–26 However,
G-CSF treatment has been associated with potential benefits
(apparent infarct healing24) and hazard (increased restenosis23),
although the results are inconsistent across studies, and further
larger trials are needed.27 Nevertheless, all of the studies to date,
including published unblinded data from another ongoing trial,28
found that G-CSF was well tolerated and increased CD34 and
leukocyte counts.
In summary, the results of this study suggest that G-CSF,
at standard hematology doses, mobilizes peripheral blood
stem cells in older patients with acute ischemic stroke.
Treatment appears to be well tolerated and safe. Further
evaluations are now required to assess whether mobilized
stem cells migrate into the brain and whether treatment
improves functional outcome.
Figure 2. CD34 count (cells/L) per
treatment block.






G-CSF events by dose regimen, Block
(No. of patients with adverse event)
Death 2 (17) 3 (13) 1.0 Block 1(1), Block 3 (1), Block 4 (1)
Complication of incident stroke 2 (17) 0
Recurrent stroke 0 1 (4)
Pneumonia 0 2 (8)
Infection 3 (25) 7 (29) 1.0 Block 1 (3), Block 2 (1), Block 3 (2), Block 5 (1)
Urinary tract infection 2 (17) 5 (21)
Pneumonia 2 (17) 3 (13)
Other 0 1 (4)
Venous thromboembolism 1 (8) 2 (8) 1.0 Block 5 (1), Block 6 (1)
Hospital re-admission 0 1(4) 1.0 Block 2 (1)
Total patients experiencing a SAE 3 (25) 7(29) 1.0
Note: Some patients had more than one event.
Frequency (%); comparison by Fisher Exact test.
SAE indicates serious adverse events.
Block 1: 1 dose 1 g/kg, Block 2: 1 dose 3 g/kg, Block 3: 1 dose 10 g/kg,
Block 4: 5 doses 1 g/kg, Block 5: 5 doses 3 g/kg, Block 6: 5 doses 10 g/kg.
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